LifeLens Continues Successful Capital Funding with NCV’s Strategic Support

June 1, 2025

LifeLens, a leading medical technology startup, is revolutionizing physiological monitoring for patients with a first-of-its-kind remote monitoring capability for a significant number of chronic conditions for at-risk patients. The startup successfully raised $20 million in Series C funding and is in negotiations for an additional $30 million from strategic investors. The company is an innovation leader with numerous patents and trade secrets. It has launched large-scale manufacturing, secured purchase contracts with U.S. agencies and military branches, and is advancing clinical trials and FDA submissions related to new go-to-market strategies. Additionally, LifeLens is finalizing a distribution agreement for cardiac monitoring, with investors eager for future funding rounds.

NCV played a pivotal role in LifeLens's growth by helping the company strategically navigate its financial management resulting in a substantial tax advantage for its investors. Beyond financial strategy, NCV has been instrumental in corporate governance by restructuring the Board and facilitating introductions to key Department of Defense personnel. NCV is also introduced LifeLens with a private investment firm specializing in the ADG&T sector, that will result in competitive advantage.

The LifeLens partnership showcases how NCV’s deep and diverse bench strength can help with management, strategic planning, practical governance, and networking, which directly translates into accelerated growth.